SpringWorks Targets Rare Tumors, But Myeloma Is The Mother Lode
Executive Summary
The company aims to file for desmoid tumors in the second half of 2022, but it has more than half a dozen combination programs with BCMA-targeting therapies in multiple myeloma.
You may also be interested in...
Advaxis To Seek New Life In Merger With Ayala
The new company will focus mainly on Ayala’s lead candidate for desmoid tumors, but minority owner Advaxis will take over management.
‘We’ll Be First With Off-The-Shelf CAR-T,’ Vows Precision Biosciences – And Hopes To Win Over Gene-Editing Skeptics
As it and its competitors have failed on the first test of durability with their allogeneic CAR-T candidates, Precision Biosciences is looking to cross the line in a sub-group of responders – as well as prove the value of its gene-editing platform.
Still Looking For The Off-The-Shelf Breakthrough, Allogene Touts Myeloma CAR-T Candidate
While a cloud hangs over the future of its CD19-targeting allogeneic candidate, Allogene points to preclinical potential of superior efficacy for ALLO-715.